

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  A61K 31/415	A1	(11) International Publication Number: <b>WO 92/16208</b>  (43) International Publication Date: 1 October 1992 (01.10.92)
(21) International Application Number: PCT/GB92/00522 (22) International Filing Date: 23 March 1992 (23.03.92)  (30) Priority data: 9106278.6 25 March 1991 (25.03.91) GB  (71) Applicant ( <i>for all designated States except US</i> ): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  (72) Inventor; and (75) Inventor/Applicant ( <i>for US only</i> ): GAZZARD, Brian, George [GB/GB]; The Westminster Hospital, Dean Ryle Street, Horseferry Road, London SW1 (GB).	(74) Agents: GIDDINGS, Peter et al.; Corporate Patents, SmithKline Beecham, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB).  (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.  Published <i>With international search report.</i>	
(54) Title: USE OF BENZIMIDAZOLE ANTHELMINTIC IN THE TREATMENT OF MICROSPORIDIAL INFECTIONS  (57) Abstract  The use of a benzimidazole anthelmintic in the treatment of microsporidial infection.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

# USE OF A BENZIMIDAZOLE ANTHELMINTIC IN THE TREATMENT OF MICROSPORIDIAL INFECTIONS

The present invention relates to the use of certain benzimidazole compounds in the treatment of diseases caused  
5 by microsporidia organisms, in particular the treatment of diarrhoea in patients infected with human immunodeficiency virus (HIV).

There are more than 500 species of the protozoa  
10 microsporidia which infect animals. Until the advent of acquired immune deficiency syndrome (AIDS) human infection was rare and confined to one or two cases of encephalitis and myositis. Now, however, microsporidium infection is common in the small intestine of HIV infected individuals  
15 and is thought to cause diarrhoea. In a recent study in the USA a third of patients in whom no other pathogen as a cause of diarrhoea had been uncovered, were found to have microsporidiosis infection in jejunal biopsy material (Human Pathology, 1990, 21(5), 475-81). Very similar figures were  
20 recently obtained in a UK study (Peacock et al., J. Clin. Path. 1991, in press). However, positive proof that Microsporidiosis is of pathogenic importance in the development of diarrhoea requires the ability to eradicate this organism with suitable chemotherapeutic agents or,  
25 alternatively, the development of suitable animal models. Such suitable chemotherapeutic agents have, until now, not been available.

The present invention fulfils this need and provides in  
30 a first aspect, the benzimidazole anthelmintic albendazole, for use in the manufacture of a medicament for use in the treatment of microsporidia infections, in particular in the treatment of microsporidia infection, for example diarrhoea-causing microsporidial infection, in patients infected with  
35 the human immunodeficiency virus (HIV).

-2-

In a broader aspect, the invention provides a benzimidazole anthelmintic for use in the manufacture of a medicament for use in the treatment of microsporidia infections, in particular in the treatment of microsporidia infection, for example diarrhoea-causing microsporidia infection, in patients infected with the human immunodeficiency virus (HIV).

The term 'benzimidazole anthelmintic' is intended to include any benzimidazole containing agent which is known to act as a broad spectrum anthelmintic. For example, in addition to albendazole, such compounds include fenbendazole, oxibendazole, mebendazole and parbendazole.

In a further aspect the present invention provides a method of treatment of microsporidial infection which comprises administration to a subject in need thereof of an effective amount of a benzimidazole anthelmintic, for example albendazole. In particular the invention provides a method for the treatment of microsporidial infection, for example diarrhoea-causing microsporidial infection, in patients infected with the human immunodeficiency virus (HIV).

When used in the present invention, the active agent is formulated in a standard pharmaceutical composition, for example in a tablet composition.

Suitable doses of active agent will be in the range of from 100 to 5000mg per day, the compound being administered in one or more discrete dosage units, once or twice a day, for as long as is necessary to treat the condition and maintain the patient free of infection. The size, frequency and duration of the dosage regimen will, of course, depend on the severity of the infection.

-3-

**RESULTS**

A study was carried out on 6 HIV infected individuals with diarrhoea and proven microsporidial infection on  
5 jejunal biopsy.

The patients were treated with albendazole (400mg, b.i.d.) and within 1 week, 5 of the 6 had had dramatic symptomatic improvement with complete loss of diarrhoea and  
10 arrested weight loss. Subsequently, two patients died of non-diarrhoeal causes and of the remaining 4 who completed one month's treatment, two relapsed.

Jejunal biopsies performed following therapy in five of  
15 these patients have shown continuing evidence of Microsporidiosis but an apparent maturation arrest so that frequent meronts are seen but mature spores are not.

## CLAIMS:

1. A benzimidazole anthelmintic for use in the  
manufacture of a medicament for use in the treatment of  
5 microsporidial infection.
2. The use according to claim 1 in which the  
benzimidazole anthelmintic is albendazole.
- 10 3. The use according to claim 2 in which the patient  
treated is also infected with human immunodeficiency virus  
(HIV).
4. The use according to claim 3 in which the  
15 microsporidial infection is a diarrhoea-causing infection.

### International Application

International Application      PCT/GB 92/00522

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
P,X	J. Protozool, volume 38, no. 6, 1991, Society of Protozoologists, 1991; E.U. Canning et al.: "In vitro and in vivo investigations of human microsporidia", pages 631-635, see page 634 -----	1,2



**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

**GB 9200522**

**SA 57702**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 07/07/92.  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-M- 4761		None	

EPO FORM P079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82